Consequently, the inhibition of PARP by genetic ablation or the use of pharmacological agents in different animal models of asthma has demonstrated therapeutic effects against lungs acting with a specific effect on immune cell recruitment and modulating the production of asthma-associated cytokine [30]. This evidence concerns the gene PARP1 and asthma.